VTRS · 10-Q · 2026Q2 · Full report
Research and Development Expense
Viatris Inc · 2026-08-06 · Importance 54 · Surprise 40 · In source text
Second-quarter 2026 R&D expense increased $29.5 million, or 13%, to $248.3 million from $218.8 million. Six-month R&D expense increased $56.1 million, or 13%, to $496.9 million from $440.8 million. The increase in both periods was primarily attributable to higher spending on the selatogrel and cenerimod development programs. Acquired IPR&D expense declined $9.8 million to $0.2 million for the six months, compared with $10.0 million in the prior-year period, because the current-period expense related only to an upfront licensing payment.
Key facts
- R&D expense for the six months ended June 30, 2026 was $496.9 million, compared to $440.8 million for the comparable prior year period, an increase of $56.1 million, primarily due to higher expenses for the selatogrel and cenerimod development programs. source
- R&D expense for the three months ended June 30, 2026 was $248.3 million, compared to $218.8 million for the comparable prior year period, an increase of $29.5 million, primarily due to higher expenses for the selatogrel and cenerimod development programs. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -1.5% | R&D expense for the six months ended June 30, 2026 was $496.9 million, compared to $440.8 million for the comparable prior year period, an… |
| operating_income | negative | realized | -0.8% | R&D expense for the three months ended June 30, 2026 was $248.3 million, compared to $218.8 million for the comparable prior year period,… |
| net_income | negative | realized | -0.8% | R&D expense for the three months ended June 30, 2026 was $248.3 million, compared to $218.8 million for the comparable prior year period,… |